Recruiting
Osteochondrodysplasia
RecruitingRegistered drugNo placebo
BMN 333 Versus Vosoritide in Children With Achondroplasia
Registered drugNo placebo
- Substances:Vosoritide
Countries:
Italy
Italy- Participants:0–17 years
- Substances:Vosoritide
Find therapies in clinical trials near you
- recruiting
- 3 961
- countries
- 28
- conditions
- 2 103
3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today
12 trials match your criteria
Recruiting
Osteochondrodysplasia
RecruitingInvestigational
A study testing the safety and effectiveness of infigratinib compared to placebo in infants and young children with achondroplasia
Investigational
- Substances:Infigratinib
Countries:
Norway
Norway- Participants:0–17 years
- Substances:Infigratinib
Recruiting
Osteochondrodysplasia
RecruitingInvestigationalNo placebo
Study on Long-Term Use of Infigratinib for Children with Achondroplasia
InvestigationalNo placebo
- Substances:Infigratinib
Countries:
France
France- Participants:0–17 years
- Substances:Infigratinib
Recruiting
Osteochondrodysplasia
RecruitingInvestigational
Study on the Effectiveness and Safety of Navepegritide for Adolescents with Achondroplasia
Investigational
- Substances:–
Countries:
Denmark
Denmark- Participants:0–17 years
Recruiting
Osteochondrodysplasia
RecruitingInvestigational
Study on the Safety and Effectiveness of TransCon CNP for Infants with Achondroplasia
Investigational
- Substances:–
Countries:
Austria
Austria- Participants:0–17 years
Recruiting
Osteochondrodysplasia
RecruitingInvestigationalNo placebo
Study on the Safety and Effectiveness of TransCon CNP for Children and Adolescents with Achondroplasia
InvestigationalNo placebo
- Substances:–
Countries:Austria
Austria- Participants:0–17 years
Not recruiting
Osteochondrodysplasia
Not recruitingInvestigational
Study on the Effects of TransCon CNP in Children Aged 2-11 with Achondroplasia
Investigational
Countries:Denmark
Denmark- Participants:0–17 years
- Substances:C-Type Natriuretic Peptide Conjugated To A Multi-Arm Polyethylene Glycol Carrier Molecule Through A Cleavable Linker
Not recruiting
Osteochondrodysplasia
Not recruitingInvestigational
Study on the Effectiveness and Safety of Infigratinib for Children Aged 3 to 17 with Achondroplasia
Investigational
- Substances:Infigratinib
Countries:France
France- Participants:0–17 years
- Substances:Infigratinib
Not recruiting
Osteochondrodysplasia
Not recruitingInvestigationalNo placebo
Study on the Effects of Navepegritide and Lonapegsomatropin in Children with Achondroplasia
InvestigationalNo placebo
- Substances:Lonapegsomatropin
Countries:Denmark
Denmark- Participants:0–17 years
- Substances:Lonapegsomatropin
Not recruiting
Osteochondrodysplasia
Not recruitingRegistered drugNo placebo
Study on the Long-Term Safety and Effectiveness of Vosoritide for Children with Achondroplasia
Registered drugNo placebo
- Substances:Vosoritide
Countries:
Germany
Germany- Participants:0–17 years
- Substances:Vosoritide
Not recruiting
Osteochondrodysplasia
Not recruitingRegistered drugNo placebo
Study on Long-Term Safety and Effects of Vosoritide in Children with Achondroplasia
Registered drugNo placebo
- Substances:Vosoritide
Countries:France
France- Participants:0–17 years
- Substances:Vosoritide
Not recruiting
Osteochondrodysplasia+1
Not recruitingInvestigationalNo placebo
Study on the Safety and Effects of SAR442501 for Children with Achondroplasia
InvestigationalNo placebo
- Substances:–
Countries:
Czechia
Czechia- Participants:0–17 years